New method for identifying proteins should have “a major impact on the development of new biologics,” U of T researcher says
Biologics are a type of drug that results from the high-tech manipulation of our own proteins, as opposed to more traditional drugs built from synthetic chemicals. Because of their success so far, scientists are racing to create new biologics – and now, a U of T researcher has developed a way to make that process more powerful.
Philip M. Kim, an associate professor in U of T’s Donnelly Centre for Cellular and Biomolecular Research, combined high-tech computer simulation and high-throughput laboratory experiments to create what he hopes will be the most effective way to discover the proteins that are key to new biologics. His research was published online in the journal Science Advances on July 20, 2016.
“A large fraction of new therapeutics these days involve engineered proteins that latch onto a drug target, for instance on a cancer cell,” says Kim, also of the departments of molecular genetics and computer science. “Finding a protein that effectively binds to a target can feel like looking for a needle in a haystack.
“Our method should open up new opportunities to find those key proteins – and make a major impact on the development of new biologics.”
Under the traditional approach to developing a biologic, researchers identify a protein of interest and then test billions of variants, either randomly generated or from a natural source, hoping to find an effective binder. But these methods allow very little control over where and how the protein performs this crucial function on its target – a major factor in its effectiveness.
Kim and his team took a different approach. They used a computer to simulate the binding process, and then designed proteins that would work on the target. This type of theoretical approach has been in development for several decades, but is still not effective enough. So Kim combined the best of both methods. Instead of randomly creating massive libraries of variants, as with the traditional approach, he used computer modelling to generate a smaller, but intelligently designed repertoire of variants. Designing each variant allows for the tight control of all its properties, in contrast to conventional approaches.
“We showed that this method gives you binders that are somewhat stronger than what you get with the conventional approach,” says Kim. “The much smaller library also solves many technical problems, and we can screen for new, previously unscreenable, targets. It’s a very exciting time for cancer research, and for biologics.”
For Kim, the next step is to produce proteins that are important to certain types of cancer, but have not been screened before due to the difficulty producing them.
Learn more: A more powerful way to develop therapeutics?
The Latest on: Biologics
via Google News
The Latest on: Biologics
- BRIEF-Heat Biologics Entered Into Collaboration With University Of Miami To Develop A Coronavirus COVID-19 Point-Of-Care Diagnostic Teston March 23, 2020 at 3:37 pm
March 23 (Reuters) - Heat Biologics Inc: * HEAT BIOLOGICS INC - ENTERED INTO COLLABORATION WITH UNIVERSITY OF MIAMI TO DEVELOP A CORONAVIRUS COVID-19 POINT-OF-CARE DIAGNOSTIC TEST * HEAT BIOLOGICS INC ...
- Biosimilar and Interchangeable Biologics: More Treatment Choiceson March 23, 2020 at 10:40 am
But what are biosimilar and interchangeable biological medications? To answer that question, it helps to first know what biological products (biologics) are. Biologics are medicines that generally ...
- Adma Biologics adds to coronavirus-stocked rally, up 48%on March 23, 2020 at 10:20 am
is up on almost a 5x surge in volume. Shares have rallied almost 128% since touching $1.45 on March 18.Investors appear bullish on the company's hyperimmune Asceniv (immune ...
- Heat Biologics and University of Miami Developing Proprietary COVID-19 Diagnostic Test Under Collaborative Research Agreementon March 23, 2020 at 6:13 am
DURHAM, NC / ACCESSWIRE / March 23, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic ...
- Schrödinger Announces Expanded Collaboration with AstraZeneca to Extend Computational Modeling Solutions to Biologicson March 23, 2020 at 4:00 am
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced an ...
- Financials WuXi Biologics (Cayman)on March 22, 2020 at 4:28 pm
Inc. Registered Shs Unitary 144A-Reg S in CNY Profit per share - WuXi Biologics (Cayman) 0.0 Sales per share - WuXi Biologics (Cayman) P/E ratio - WuXi Biologics (Cayman) WuXi Biologics (Cayman) Inc.
- Samsung Biologics Adds Greater Expertise and Diversity to Its Boardon March 20, 2020 at 5:00 am
announced the appointment and expansion of its board of directors at its 9 th annual general meeting of shareholders that took place on March 20th. In the course of expanding its business model from a ...
- AGC Biologics to Participate in Virtual BIO-Europe Springon March 19, 2020 at 9:58 am
/PRNewswire/ -- AGC Biologics is pleased to be a gold sponsor of BIO-Europe Spring, Europe's largest springtime biotech partnering event. In order to ...
- Shares of Heat Biologics rise on plans to develop COVID-19 vaccine candidateon March 17, 2020 at 11:35 am
Heat Biologics Inc. disclosed Tuesday in a financial filing that its COVID-19 vaccine candidate had been added to the World Health Organization's ...
- US$11.00: That's What Analysts Think ADMA Biologics, Inc. Is Worth After Its Latest Resultson March 17, 2020 at 7:25 am
One of the biggest stories of last week was how ADMA Biologics, Inc. (NASDAQ:ADMA) shares plunged 30% in the ...
via Bing News